Literature DB >> 23646423

[Electrophysiological characteristics of EABR and its value assessment of cochlear implant].

Yu Wang1, Tao Pan, Na Zhou, Furong Ma.   

Abstract

OBJECTIVE: To evaluate the electrophysiological characteristics of electrically evoked auditory brainstem responses (EABR) and its application in cochlear implantation, especially in evaluating acoustic nerve survival.
METHOD: An auditory evoked potential instrument was used to record responses and Cochlear Nucleus 24CA implants were used to generate electrical stimulation. We measured EABR in 23 patients with cochlear implants and compared EABR with behavioral measures and neural response telemetry (NRT). RESULT: EABR III-V waveforms were recognized in all of the 23 patients. The characteristics and origins of EABR waveforms were similar to those of ABR. The average EABR threshold was (172.61 +/- 14.61) CL. At 20 CL above threshold, the average latencies of Wave III, V were (2.93 +/- 0.18)ms, (4.80 +/- 0.28)ms which were 1-2 ms shorter than ABR latencies. But III-V intervals remained at (1.86 +/- 0.18)ms. EABR thresholds were strongly correlated with behavioral performance and NRT thresholds, while EABR input-output function is correlated with behavioral dynamic range (DR).
CONCLUSION: EABR is such an effective method to objectively evaluate the function of auditory pathway which can estimate residual spiral ganglion cell count. This is consistent with the foreign study leading to the conclusion that DR reflects spiral ganglion cell survival.

Entities:  

Mesh:

Year:  2013        PMID: 23646423

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1001-1781


  1 in total

1.  E-ABR in Patients with Cochlear Implant: A Comparison between Patients with Malformed Cochlea and Normal Cochlea.

Authors:  Arianna Di Stadio; Laura Dipietro; Antonietta De Lucia; Franco Trabalzini; Giampietro Ricci; Francesco Martines; Vincenzo Pastore; Antonio della Volpe
Journal:  J Int Adv Otol       Date:  2019-08       Impact factor: 1.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.